Evidence map›Paper›PMID 30526421›Full record

ArticlePathogens and global health2018

Patient and treatment pathways for toxoplasmosis in the United States: data analysis of the Vizient Health Systems Data from 2011 to 2017.

Kathy Belk, Mark P Connolly, Lisa Schlesinger, Ruben R Ben-Harari

Open access · bronzeAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathogens and global health, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.0field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Frontiers in microbiology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Kathy Belka Health Clarity Solutions , Mooresville , NC , USA.
Mark P Connollyb Department of Pharmacy, Unit of Pharmacoepidemiology & Pharmacoeconomics , University of Groningen , Groningen , The Netherlands.ORCID 0000-0002-1886-745X
Lisa Schlesingerd Sage Therapeutics , Cambridge , MA , USA.
Ruben R Ben-Hararie Department of Medical Affairs , Vyera Pharmaceuticals , New York , NY , USA.ORCID 0000-0001-6531-2409
Clinical Solutions · USSage Therapeutics (United States) · USUniversity of Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Toxoplasmosis causes substantial morbidity and mortality in the United States (US). Clinical manifestations to toxoplasmosis vary and there is limited information on incidence or treatment patterns in the US. Treatment pathways for pyrimethamine-based regimens and trimethoprim-sulfamethoxazole (TMP-SMX) for toxoplasmosis hospitalizations were investigated using the Vizient Health Systems inpatient and outpatient data. Between January 1

Indexed as

AdolescentAdultAgedAged, 80 and overAIDS-Related Opportunistic InfectionsAntiprotozoal AgentsChildChild, PreschoolCritical PathwaysDatabases, FactualFemaleHospitalizationHumansInfantInfant, NewbornMaleAntiprotozoal AgentsPyrimethamineTrimethoprim, Sulfamethoxazole Drug Combinationcerebral toxoplasmosisCharlson Comorbidity IndexICD-10 codeICD-9 codeincidencepyrimethamineToxoplasma gondiitoxoplasmosistoxoplasmosis encephalitis

Identifiers

PMID30526421
PMCPMC6327601
OpenAlexW2904549082

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.